Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

ZVRA

Zevra Therapeutics Inc

Oct 08 • 04:00PM ET

8.37

Dollar change +0.58
Percentage change 7.45	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IWN IWO VTWO SURI IWC ITOT RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.68	Insider Own	0.61%	Shs Outstand	52.62M	Perf Week	22.19%
Market Cap	440.43M	Forward P/E	-	EPS next Y	-0.30	Insider Trans	7.36%	Shs Float	52.30M	Perf Month	15.77%
Income	-65.75M	PEG	-	EPS next Q	-0.41	Inst Own	30.80%	Short Float	7.20%	Perf Quarter	52.88%
Sales	23.99M	P/S	18.36	EPS this Y	-21.56%	Inst Trans	15.10%	Short Ratio	3.47	Perf Half Y	69.43%
Book/sh	0.77	P/B	10.82	EPS next Y	80.80%	ROA	-52.61%	Short Interest	3.77M	Perf Year	82.35%
Cash/sh	0.75	P/C	11.22	EPS next 5Y	-	ROE	-130.22%	52W Range	3.89 - 8.95	Perf YTD	27.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	51.89%	ROI	-71.97%	52W High	-6.48%	Beta	1.94
Dividend TTM	-	Quick Ratio	2.00	Sales past 5Y	44.97%	Gross Margin	46.06%	52W Low	115.17%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	2.00	EPS Y/Y TTM	-77.61%	Oper. Margin	-309.83%	RSI (14)	63.49	Volatility	7.67% 7.68%
Employees	69	Debt/Eq	1.83	Sales Y/Y TTM	45.00%	Profit Margin	-274.10%	Recom	1.00	Target Price	19.86
Option/Short	Yes / Yes	LT Debt/Eq	1.81	EPS Q/Q	-217.07%	Payout	-	Rel Volume	1.96	Prev Close	7.79
Sales Surprise	1.92%	EPS Surprise	-5.73%	Sales Q/Q	-47.47%	Earnings	Aug 13 AMC	Avg Volume	1.09M	Price	8.37
SMA20	10.77%	SMA50	14.96%	SMA200	41.52%	Trades		Volume	2,123,694	Change	7.45%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Initiated	Guggenheim	Buy	$20
Sep-24-24	Reiterated	Maxim Group	Buy	$18 → $25
Sep-24-24	Initiated	JMP Securities	Mkt Outperform	$17
Apr-02-24	Reiterated	Maxim Group	Buy	$12 → $18
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy	$12

Sep-25-24 06:22AM	Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? (Zacks) -8.77%
Sep-24-24 07:30AM	Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 (GlobeNewswire) +9.10%
Sep-23-24 04:12AM	FDA approves Zevra Therapeutics Miplyffa for Niemann-Pick disease (Pharmaceutical Technology) -5.96%
Sep-20-24 01:27PM	Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease (Benzinga)
12:08PM	Zevra Therapeutics' MIPLYFFA (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C (GlobeNewswire)
08:30AM	Loading…
Sep-06-24 08:30AM	Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium (GlobeNewswire)
Aug-29-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 05:30PM	Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	Zevra Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-09-24 12:00AM	Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) -10.55%
Aug-08-24 04:01PM	Zevra Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-07-24 09:34AM	Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference (GlobeNewswire) -8.12%
Aug-06-24 10:00AM	Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline (Zacks)
Aug-05-24 11:13AM	Zevra wins FDA panel backing for previously rejected arimoclomol (Pharmaceutical Technology) +25.08%
05:50PM	Loading…
Aug-02-24 05:50PM	FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C (GlobeNewswire)
Jul-30-24 08:38AM	Zevra Therapeutics to Report Second Quarter 2024 Financial Results (GlobeNewswire) -5.82%
Jul-10-24 03:04PM	Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug (Zacks)
08:24AM	Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains? (Zacks)
07:48AM	AbbVie names new R&D head; Arcutis eczema cream approved (BioPharma Dive)
Jul-09-24 03:27PM	FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base (Benzinga) +21.94%
09:00AM	Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
Jun-25-24 07:30AM	Zevra Therapeutics Expands Executive Leadership Team (GlobeNewswire)
Jun-18-24 07:30AM	Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders (PR Newswire)
Jun-03-24 11:00AM	Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting (GlobeNewswire)
May-09-24 12:24PM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Events (GlobeNewswire)
03:03AM	Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 11:57AM	ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:12AM	Zevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ... (GuruFocus.com)
08:15AM	Loading…
08:15AM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:23AM	Zevra Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-01-24 07:30AM	Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024 (GlobeNewswire)
Apr-29-24 07:30AM	Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024 (GlobeNewswire)
Apr-15-24 05:01PM	Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting (GlobeNewswire)
Apr-10-24 07:30AM	Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility (GlobeNewswire)
Apr-01-24 12:46PM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.03%
Mar-29-24 12:07PM	Q4 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 09:52PM	ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -11.03%
06:11PM	Zevra Therapeutics Inc (ZVRA) Earnings: A Mixed Bag Against Analyst Estimates with Significant ... (GuruFocus.com)
04:53PM	Zevra Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:32PM	Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Mar-26-24 04:30PM	Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia (GlobeNewswire)
Mar-25-24 04:30PM	Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-24 10:00AM	Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know (Zacks)
Mar-18-24 07:30AM	Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024 (GlobeNewswire)
Mar-07-24 11:56AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-04-24 07:30AM	Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C (GlobeNewswire) -12.15%
Feb-28-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-15-24 03:49AM	Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks) +8.79%
Feb-06-24 07:30AM	Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-23-24 07:30AM	Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors (GlobeNewswire)
Jan-08-24 07:30AM	Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C (GlobeNewswire) +6.90%
Jan-04-24 08:55AM	Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer (GlobeNewswire)
Dec-27-23 07:30AM	Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration (GlobeNewswire) +10.71%
Nov-20-23 07:30AM	Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company (GlobeNewswire)
Nov-12-23 08:42AM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:17AM	Zevra Therapeutics Inc (ZVRA) Reports Q3 2023 Financial Results (GuruFocus.com)
07:08AM	Zevra Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 07:30AM	Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET (GlobeNewswire)
Oct-19-23 07:30AM	Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October (GlobeNewswire)
Oct-10-23 07:30AM	Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director (GlobeNewswire)
Oct-05-23 07:30AM	Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting (GlobeNewswire)
Oct-02-23 07:30AM	Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia (GlobeNewswire)
Sep-20-23 07:30AM	Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-23 08:00PM	Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023 (GlobeNewswire)
Sep-05-23 07:30AM	Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -6.51%
Sep-04-23 09:55AM	How Much Upside is Left in Zevra Therapeutics (ZVRA)? Wall Street Analysts Think 248.51% (Zacks)
Sep-01-23 07:31AM	Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up (Zacks) +6.11%
Aug-31-23 12:13PM	Struggling Newton biotech Acer Therapeutics scooped up by Florida firm (American City Business Journals)
07:30AM	Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product (GlobeNewswire)
Aug-19-23 07:40AM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-17-23 09:55AM	Can Zevra Therapeutics (ZVRA) Climb 227.55% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-15-23 12:15AM	Q2 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:42AM	Zevra Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:30AM	Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-07-23 04:45PM	Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster (GlobeNewswire) +7.00%
Aug-02-23 07:30AM	Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023 (GlobeNewswire)
Jul-19-23 10:30AM	Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long (Simply Wall St.)
07:30AM	Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference (GlobeNewswire)
Jun-20-23 07:30AM	Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 (GlobeNewswire) +6.88%
Jun-13-23 07:30AM	Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest (GlobeNewswire)
Jun-03-23 07:30AM	Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 (GlobeNewswire)
May-16-23 06:22AM	Q1 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.11%
May-15-23 05:55PM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:59PM	Zevra Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:05PM	Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 07:30AM	Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023 (GlobeNewswire)
May-09-23 07:30AM	Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023 (GlobeNewswire) -9.96%
May-08-23 07:30AM	Zevra Announces Board of Directors and Leadership Changes (GlobeNewswire)
May-03-23 07:30AM	Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy (GlobeNewswire)
Apr-17-23 04:05PM	Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevras Transformation Strategy (GlobeNewswire)
06:18AM	Why Investors Shouldn't Be Surprised By Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 31% Share Price Surge (Simply Wall St.)
Apr-04-23 07:30AM	Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy (GlobeNewswire)
Mar-30-23 07:30AM	Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors (GlobeNewswire)
Mar-17-23 07:30AM	Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative (GlobeNewswire)
Mar-15-23 07:26AM	Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders (GlobeNewswire) -5.01%
Mar-07-23 07:00AM	Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates (GlobeNewswire) -19.44%

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Clifton R. LaDuane	CFO & Treasurer	Jul 17 '24	Buy	6.77	2,000	13,540	18,469	Jul 17 05:54 PM
Anderson Thomas	Director	Jul 16 '24	Buy	6.81	10,000	68,065	20,000	Jul 16 04:39 PM
Bode John B	Director	Jul 12 '24	Buy	5.87	10,000	58,661	30,000	Jul 15 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZVRA

Zevra Therapeutics Inc

Upgrade your FINVIZ experience